GLP-131, Phase I, BMF-650 in obese, otherwise healthy volunteers, with completion of single- and multiple-ascending dose cohorts and final 28-day weight-loss data expected in the second quarter of 2026.

BMF-650 - Biomea Fusion

Jan 13, 2026